SEARCH:   Advanced

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Kluijtmans, L. A.J. Articles by Blom, H. J. Search for Related Content PubMed PubMed Citation Articles by Kluijtmans, L. A.J. Articles by Blom, H. J. Related Collections Hemostasis, Thrombosis, and Vascular Biology Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, Vol. 91 No. 6 (March 15), 1998: pp. 2015-2018 Homozygous Cystathionine -Synthase Deficiency, Combined With Factor V Leiden or Thermolabile Methylenetetrahydrofolate Reductase in the Risk of Venous Thrombosis By Leo A.J. Kluijtmans, Godfried H.J. Boers, Bert Verbruggen, Frans J.M. Trijbels, Irena R.O. Nováková, and Henk J. Blom From the Departments of Pediatrics, Internal Medicine, and Haematology, Central Laboratory for Haematology, University Hospital Nijmegen, the Netherlands.     ABSTRACT Abstract Introduction Methods Results Discussion References Severe hyperhomocysteinemia in its most frequent form, is caused by a homozygous enzymatic deficiency of cystathionine -synthase (CBS). A major complication in CBS deficiency is deep venous thrombosis or pulmonary embolism. A recent report by Mandel et al (N Engl J Med 334:763, 1996) postulated factor V Leiden (FVL) to be an absolute prerequisite for the development of thromboembolism in patients with severe hyperhomocysteinemia. We studied 24 patients with homocystinuria caused by homozygous CBS deficiency from 18 unrelated kindreds for FVL and for the 677CT mutation in the methylenetetrahydrofolate reductase (MTHFR) gene and investigated their possible interaction in the risk of venous thrombosis. Thrombotic complications were diagnosed in six patients, of whom only one was a carrier of FVL. On the contrary, thermolabile MTHFR caused by the 677CT mutation, was frequently observed among homocystinuria patients, especially among those with thromboembolic complications: three of six homocystinuria patients who had suffered from a thromboembolic event had thermolabile MTHFR. These data indicate that FVL is not an absolute prerequisite and probably not even a major determinant of venous thrombosis in homocystinuria, but, interestingly, thermolabile MTHFR may constitute a significant risk factor for thromboembolic complications in this inborn error of methionine metabolism.     INTRODUCTION Abstract Introduction Methods Results Discussion References HOMOCYSTINURIA, characterized by severe hyperhomocysteinemia, may have its origin in deficiencies in enzymes involved in methionine metabolism.1-3 The concomitant finding of an extremely high risk of premature vascular disease in patients suffering from homocystinuria has led to the "homocysteine theory,"4 which hypothesizes that a severely elevated homocysteine concentration, irrespective of its cause, is associated with vascular pathology in arteriosclerosis and thrombosis. The most frequent cause of homocystinuria is a homozygous deficiency of cystathionine -synthase (CBS), the first enzyme in the transsulphuration pathway.5 This classical homocystinuria is, next to the life-threatening complications from the vascular system, characterized by ectopia lentis, skeletal abnormalities, and mental retardation.5 In a large international survey among patients with homocystinuria caused by CBS deficiency, Mudd et al6 observed one or more episodes of a thromboembolic event in 158 (25%) of 629 homocystinuria patients. These thromboembolic events can be subdivided in cerebrovascular accidents (31%), venous complications (51%, of which 12% represent pulmonary embolism), myocardial infarctions (4%), and peripheral arterial complications (11%). It could be calculated that each untreated patient had about a 50% chance to suffer from such an event under the age of 30 years. Resistance to activated protein C (APC resistance) caused by a single R506Q mutation in the factor V gene, the so-called factor V Leiden (FVL) mutation,7 is the most predominant hereditary cause of venous thrombosis identified so far.8 Heterozygous individuals have approximately an eightfold higher risk on thrombosis,9 whereas the risk in homozygotes is increased about 80-fold.10 In the Physicians' Health Study including about 15,000 apparently healthy men, Ridker et al11 reported an association also between this mutation and the occurrence of deep venous thrombosis after a mean follow-up of 8.6 years but not with myocardial infarction and stroke. Only a few studies have investigated a possible interaction between hyperhomocysteinemia and APC resistance caused by FVL in the risk of thrombosis. In a recent study by Den Heijer et al,12 mild hyperhomocysteinemia was associated with an increased risk for a first occurrence of deep-vein thrombosis, but they did not observe an enhanced thrombotic risk in jointly affected patients. These results have been confirmed in a study of D'Angelo et al.13 On the other hand, Ridker et al14 noticed a substantially increased risk of developing future thrombosis in apparently healthy men with coexistent hyperhomocysteinemia and FVL. In severe hyperhomocysteinemia data are conflicting. In seven highly consanguineous families including 45 patients with homocystinuria of different origins, Mandel et al15 observed thrombosis in only those homocystinuria patients with concomitant heterozygous or homozygous FVL. These results were challenged by Quéré et al16 who reported the absence of such an interaction in 15 homocystinuria patients with genetically proven CBS deficiency from 13 unrelated kindreds. A common homozygous 677CT mutation in the methylenetetrahydrofolate reductase (MTHFR) gene has been shown to be a major cause of mildly elevated plasma homocysteine concentrations17,18 and has been investigated as a risk factor for venous thrombosis.19,20 The effect of the homozygous 677CT mutation on the risk of deep venous thrombosis in CBS-deficient patients is unknown. In the present study, we analyzed 24 homozygous CBS-deficient patients from 18 unrelated kindreds for FVL, and the 677CT mutation in the MTHFR gene. We investigated whether a possible interaction between FVL, thermolabile MTHFR, and the severe hyperhomocysteinemia caused by CBS deficiency, leads to an enhancement of the excessive thrombotic risk in patients with joint abnormalities.     MATERIALS AND METHODS Abstract Introduction Methods Results Discussion References Patients.   Twenty-four patients, 14 men and 10 women from 18 unrelated kindreds, with homocystinuria caused by CBS deficiency were studied for FVL and the MTHFR 677CT polymorphism. Twenty-three patients were pyridoxine responsive. The diagnosis of homocystinuria caused by CBS deficiency in patients was made at a mean age of 24.7 years (range 4 to 54), by establishing severe hyperhomocysteinemia and homocystinuria, hypermethioninemia, and decreased levels of cysteine in plasma. Furthermore, CBS activities measured in extracts of cultured fibroblasts21,22 were less than 2% of the mean in controls, except in one patient, in whom we observed CBS activities in the heterozygous range. However, in this patient we were able to show a defective CBS regulation by S-adenosylmethionine (AdoMet) leading to severe hyperhomocysteinemia.23 Up to now, in 18 of 24 patients homozygous CBS deficiency was confirmed by molecular genetic analysis of the CBS cDNA18,23,24 (Kluijtmans et al, unpublished results). Deep venous thrombosis was diagnosed by means of flebography and pulmonary embolism by pulmonary perfusion-ventilation scintigraphy. Mutation detection.   DNA was isolated from peripheral blood lymphocytes by a standard method.25 FVL was investigated by allele-specific polymerase chain reaction amplification and capillary electrophoresis with on-line ultraviolet detection, as described by Van der Locht et al.26 Screening for the 677CT polymorphism in the MTHFR gene was performed essentially according to Frosst et al.17 Biochemical analysis.   Determination of homocystine, homocysteine-cysteine mixed disulfide, and methionine in serum of the homocystinuria patients has been performed as described earlier by us.27 The total amount of nonprotein-bound homocysteine was calculated as twice the concentration of homocystine plus the concentration of the homocysteine-cysteine mixed disulfide. Statistics.   The differences in MTHFR genotype distributions and allele frequencies among homocystinuria patients versus Dutch controls28 have been assessed by (Yates corrected) 2 analyses. Differences in serum homocysteine and methionine concentrations in carriers versus noncarriers of the homozygous 677CT mutation in the MTHFR gene have been assessed by nonparametric Wilcoxon-Mann-Whitney-U tests. All P values reported are two-tailed, and P < .05 was considered statistically significant.     RESULTS Abstract Introduction Methods Results Discussion References Of 24 homocystinuria patients, 3 individuals, all belonging to the same kindred, were carriers of FVL; no homozygotes for FVL were observed. In the study group, 6 individuals, mean age, 23 years (range, 9 to 40), suffered from a thrombotic complication; 4 patients (3 men and 1 woman) had deep venous thrombosis and 2 patients (both women) had pulmonary embolism, whereas 18 homocystinuria patients remained free of venous thrombotic disease. Venous thrombosis occurred in these 6 patients before the start of homocysteine-lowering treatment, which had been prescribed immediately after the diagnosis of homocystinuria had been established. All 6 patients with thrombosis proved to be vitamin B6 responders. Only one thrombotic event occurred in a homocystinuria patient with concomitant FVL. Five patients suffered from thrombosis without the presence of FVL (Table 1).   View this table: [in this window] [in a new window]   Table 1. Association Between Factor V Leiden and Thermolabile MTHFR Genotype and the Occurrence of Thrombosis in 24 Homozygous CBS-Deficient Patients We also screened for the 677CT polymorphism in the MTHFR gene in these patients. The overall allele frequency of the T-allele was 0.44, which is significantly different from the allele frequency (0.30) observed in Dutch controls (2 = 3.88; DF = 1; P = .049). In our study group, we observed 5 (21%) homozygotes for the T-allele, 11 (46%) heterozygotes, and 8 (33%) wild-type (CC) individuals, which statistically tends to be significantly different from the genotype distribution in Dutch controls (2 = 5.43; Degrees of Freedom (DF) = 2; P = .07). The relatively high frequency of the homozygous TT genotype among these homocystinuria patients was not caused by a high prevalence of TT genotype among siblings (data not shown). Three of six patients with thrombosis had the homozygous TT genotype (Table 1), one was heterozygous, whereas two patients had the CC genotype. We assessed the serum nonprotein-bound homocysteine and methionine concentrations and the homocysteine/methionine ratio in the homocystinuria patients (n = 21); 5 patients with the concomitant homozygous TT genotype were compared with 16 heterozygous (CT) and wild-type (CC) individuals (Table 2). Mean serum homocysteine concentration in concomitant carriers of the TT genotype was elevated compared with those observed in individuals with CT and CC genotypes (P = .6). Methionine concentrations were less elevated in TT carriers, whereas the homocysteine/methionine ratio was slightly increased compared with noncarriers (P = .4 and P = .7, respectively). However, all these differences did not reach statistical significance because of the small number of patients.   View this table: [in this window] [in a new window]   Table 2. Nonprotein-Bound Homocysteine and Methionine Concentrations in Homozygous CBS-Deficient Patients With and Without Concomitant Homozygosity for the 677C  T Mutation in the MTHFR Gene     DISCUSSION Abstract Introduction Methods Results Discussion References In homocystinuria caused by CBS deficiency, venous thrombotic events are a common manifestation; about 13% of a large cohort of homocystinuria patients studied retrospectively suffered from one or more episodes of venous thrombosis.6 This observation, and the concomitant finding of a high risk for arteriosclerosis in homocystinuria, led to the conclusion that severely elevated plasma homocysteine concentrations constitute a risk factor for both arteriosclerosis and thrombosis. Recently, Bertina et al7 described a point mutation in the factor V gene, an R506Q substitution, which renders factor V resistant to cleavage by activated protein C. Several studies have investigated either APC resistance,11,29-31 mild hyperhomocysteinemia,32-36 or thermolabile MTHFR19,20,37 as risk factors for venous thrombosis. Only a few reports have investigated a possible interaction between hyperhomocysteinemia or thermolabile MTHFR and FVL in the risk of thrombosis.12-16,20,37 However, both in mild and severe hyperhomocysteinemia, data are confusingly conflicting. Very recently, a synergistic interaction between mild hyperhomocysteinemia and FVL was reported from the Physicians' Health Study, in which a 20-fold higher risk on thrombosis was calculated in jointly affected individuals compared with nonaffected subjects.14 These results were in contradiction with those reported by Den Heijer et al12 and D'Angelo et al.13 Cattaneo et al20 reported a synergistic interaction between thermolabile MTHFR and FVL in Italian thrombosis patients. However, the numbers of jointly affected individuals in all these studies were relatively small. Mandel et al15 reported on an interaction between severe hyperhomocysteinemia and FVL. In their study they observed thrombotic events only in patients with both inherited anomalies, which led them to conclude that FVL is a prerequisite for the occurrence of thrombosis in homocystinuria patients. However, the results in their study may have been biased by the high degree of consanguinity in their families, which is reflected in the presentation of other rare inborn errors of metabolism, like phenylketonuria, lysinuric protein intolerance, and Immerslund-Gräsbeck syndrome in some of their pedigrees.15 Our present study contradicts the hypothesis of Mandel et al.15 In our study group, five of six homocystinuria patients, who suffered from one or more thrombotic events, were not carriers of an FVL allele. The same results were obtained by Quéré et al,16 who also concluded that FVL is not an absolute requirement for the development of thrombosis in homozygous CBS-deficient patients. In their study, 5 of 15 homocystinuria patients had presented with venous thrombosis, of which only 2 individuals had FVL. Thus, 3 patients without the FVL mutation had had venous thrombosis.16 A remarkable finding in the present study was the relatively high frequency of the MTHFR TT-genotype among our six homocystinuria patients who suffered from a thrombotic event. In this subgroup, three (50%) of six patients had the MTHFR TT-genotype, suggesting that, although the number of individuals is small, thermolabile MTHFR might be an important additional factor in the risk of thrombosis in homozygous CBS-deficient patients. In the 18 homocystinurics who did not present with thrombotic complications, the frequency of the MTHFR TT-genotype was approximately 10%, virtually identical to that observed in the Dutch population.28 This major contributing effect of the 677CT mutation may be explained by the coordinate regulation of homocysteine metabolism by AdoMet.38,39 In homocystinuria caused by CBS deficiency, AdoMet concentrations are elevated,40 which results in an inhibition of MTHFR. In case of a combination with the homozygous 677CT mutation, this joint effect will be an even more substantial reduction of homocysteine remethylation, theoretically leading to a further accumulation of serum homocysteine and an attenuation in the increase of serum methionine. The measurement of serum nonprotein-bound homocysteine and methionine in concomitant TT carriers and noncarriers supports this hypothesis: serum homocysteine was slightly higher, whereas serum methionine was less elevated in these patients with concomitant thermolabile MTHFR. However, probably because of the small sample sizes, these differences did not reach statistical significance. In our study group, the three patients with FVL were siblings, and only one of them presented with thrombosis. Interestingly, the patient with thrombosis was a carrier of the MTHFR TT-genotype as well, in contrast to his two siblings. Institution of anticoagulation and homocysteine lowering treatment after diagnosis could have prevented the development of thrombosis in these two subjects. However, both individuals were untreated for a long period, 21 and 26 years, respectively, at which ages in five of six homocystinurics deep venous thrombosis had developed already. In this pedigree, thermolabile (TT) MTHFR might have been a critical contributing factor in the risk of thrombosis in the homocystinuric sibling with joint anomalies.     FOOTNOTES    Submitted September 8, 1997; accepted November 3, 1997.    Address reprint requests to Godfried H.J. Boers, MD, PhD, Department of Internal Medicine, University Hospital Nijmegen, PO Box 9101, 6500 HB Nijmegen, the Netherlands.    The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. section 1734 solely to indicate this fact.     ACKNOWLEDGMENT The authors greatly acknowledge Mia Willemsen and Kitty Verbeek for expert technical assistance.     REFERENCES Abstract Introduction Methods Results Discussion References 1. Finkelstein JD, Mudd HS, Laster FIK: Homocystinuria due to cysthathionine synthetase deficiency: The mode of inheritance. Science 146:785, 1964[Abstract/Free Full Text] 2. Mudd HS, Uhlendorf BW, Freeman JM, Finkelstein JD, Shih VE: Homocystinuria associated with decreased methylenetetrahydrofolate reductase activity. Biochem Biophys Res Commun 46:905, 1972[Medline] [Order article via Infotrieve] 3. Mudd SH, Levy HL, Abeles RH: A derangement in B12 metabolism leading to homocystinuria, cystathioninemia and methylmalonuc aciduria. Biochem Biophys Res Commun 35:121, 1969[Medline] [Order article via Infotrieve] 4. McCully KS: Vascular pathology of homocysteinemia: Implications for the pathogenesis of arteriosclerosis. Am J Pathol 56:111, 1969[Medline] [Order article via Infotrieve] 5. Mudd HS, Levy HL, Skovby F: Disorders of transsulfuration, in Scriver CR, Beaudet AL, Sly WS, Vall D (eds): The Metabolic and Molecular Basis of Inherited Disease. New York, NY, McGraw-Hill, 1995, p 1279 6. Mudd HS, Skovby F, Levy HL, Pettigrew KD, Wilcken B, Pyeritz RE, Andria G, Boers GHJ, Bromberg IL, Cerone R, Fowler B, Grobe H, Schmidt H, Schweitzer L: The natural history of homocystinuria due to cystathionine -synthase deficiency. Am J Hum Genet 37:1, 1985[Medline] [Order article via Infotrieve] 7. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, De Ronde H, Van der Velden PA, Reitsma PH: Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369:64, 1994[Medline] [Order article via Infotrieve] 8. Zöller B, Dahlbäck B: Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet 343:1536, 1994[Medline] [Order article via Infotrieve] 9. Koster T, Rosendaal FR, De Ronde H, Briët E, Vandenbroucke JP, Bertina RM: Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden thrombophilia study. Lancet 342:1503, 1993[Medline] [Order article via Infotrieve] 10. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH: High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 85:1504, 1995[Abstract/Free Full Text] 11. Ridker PM, Hennekens CH, Lindpainter K, Stampfer MJ, Eisenberg PR, Miletich JP: Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 332:912, 1995[Abstract/Free Full Text] 12. Den Heijer M, Koster T, Blom HJ, Bos GMJ, Briët E, Reitsma PH, Vandenbroucke JP, Rosendaal FR: Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 334:759, 1996[Abstract/Free Full Text] 13. (letter) D'Angelo A, Fermo I, D'Angelo SV: Thrombophilia, homocystinuria, and mutation of the factor V gene. N Engl J Med 335:289, 1996[Free Full Text] 14. Ridker PM, Hennekens CH, Selhub J, Miletich JP, Malinow MR, Stampfer MJ: Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism. Circulation 95:1777, 1997[Abstract/Free Full Text] 15. Mandel H, Brenner B, Berant M, Rosenberg N, Lanir N, Jakobs C, Fowler B, Seligsohn U: Coexistence of hereditary homocystinuria and factor V Leiden-effect on thrombosis. N Engl J Med 334:763, 1996[Abstract/Free Full Text] 16. (letter) Quéré I, Lamarti H, Chadefaux-Vekemans B: Thrombophilia, homocystinuria, and mutation of the factor V gene. N Engl J Med 335:289, 1996 17. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GHJ, Den Heijer M, Kluijtmans LAJ, Van den Heuvel LPWJ, Rozen R: A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase. Nature Genet 10:111, 1995[Medline] [Order article via Infotrieve] 18. Kluijtmans LAJ, Van den Heuvel LPWJ, Boers GHJ, Stevens EMB, Frosst P, Van Oost BA, Trijbels JMF, Rozen R, Blom HJ: Molecular genetic analysis in mild hyperhomocysteinemia: A common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet 58:35, 1996[Medline] [Order article via Infotrieve] 19. Arruda VR, Von Zuben PM, Chiaparini LC, Annichino-Bizzacchi JM, Costa FF: The mutation Ala677Val in the methylenetetrahydrofolate reductase gene: A risk factor for arterial disease and venous thrombosis. Thromb Haemost 77:818, 1997[Medline] [Order article via Infotrieve] 20. (abstr) Cattaneo M, Tsai MY, Bucciarelli P, Taioli E, Zighetti ML, Bignell M, Mannucci PM: A common mutation in the methylenetetrahydrofolate reductase gene (C677T) increases the risk for deep-vein thrombosis in patients with mutant factor V (factor V:Q506). Blood 88:285a, 1996 21. Boers GHJ, Fowler B, Smals AGH, Trijbels JMF, Leermakers AI, Kleijer WJ, Kloppenborg PWC: Improved identification of heterozygotes for homocystinuria due to cystathionine synthase deficiency by the combination of methionine loading and enzyme determination in cultured fibroblasts. Hum Genet 69:164, 1985[Medline] [Order article via Infotrieve] 22. Fowler B, Kraus JP, Packman S, Rosenberg LE: Homocystinuria: Evidence for three distinct classes of cystathionine -synthase mutant in cultured fibroblasts. J Clin Invest 61:645, 1978 23. Kluijtmans LAJ, Boers GHJ, Stevens EMB, Renier WO, Kraus JP, Trijbels JMF, Van den Heuvel LPWJ, Blom HJ: Defective cystathionine -synthase regulation by S-adenosylmethionine in a partially pyridoxine responsive homocystinuria patient. J Clin Invest 98:285, 1996[Medline] [Order article via Infotrieve] 24. Kluijtmans LAJ, Blom HJ, Boers GHJ, Van Oost BA, Trijbels JMF, Van den Heuvel LPWJ: Two novel missense mutations in the cystathionine -synthase gene in homocystinuric patients. Hum Genet 96:249, 1995[Medline] [Order article via Infotrieve] 25. Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16:1215, 1988[Free Full Text] 26. Van der Locht LTF, Kuypers AWHM, Verbruggen BW, Linssen PCM, Nováková IRO, Mensink EJBM: Semi-automated detection of the factor V mutation by allele specific amplification and capillary electrophoresis. Thromb Haemos 74:1276, 1995[Medline] [Order article via Infotrieve] 27. Boers GHJ, Smals AGH, Trijbels JMF, Leermakers AI, Kloppenborg PWC: Unique efficiency of methionine metabolism in premenopausal women may protect against vascular disease in the reproductive years. J Clin Invest 72:1971, 1983 28. Kluijtmans LAJ, Kastelein JJP, Lindemans J, Boers GHJ, Heil SG, Bruschke AVG, Jukema JW, Van den Heuvel LPWJ, Trijbels JMF, Boerma GJM, Verheugt FWA, Willems F, Blom HJ: Thermolabile methylenetetrahydrofolate reductase in coronary artery disease. Circulation 96:2573, 1997[Abstract/Free Full Text] 29. Perry DJ, Pasi KJ: Resistance to activated protein C and factor V Leiden. Q J Med 90:379, 1997[Abstract/Free Full Text] 30. Laffan MA, Tuddenham EGD: Inherited thrombophilia. Q J Med 90:375, 1997[Free Full Text] 31. Svennson PJ, Dahlbäck B: Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 330:517, 1994[Abstract/Free Full Text] 32. Falcon CR, Cattaneo M, Panzeri D, Martinelli I, Mannuci PM: High prevalence of hyperhomocyst(e)inemia in patients with juvenile venous thrombosis. Arterioscler Thromb 14:1080, 1994[Abstract/Free Full Text] 33. Den Heijer M, Blom HJ, Gerrits WBJ, Rosendaal FR, Haak HL, Wijermans PW, Bos GMJ: Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis? Lancet 345:882, 1995[Medline] [Order article via Infotrieve] 34. Brattström L, Tengborn L, Lagerstedt C, Israelsson B, Hultberg BL: Plasma homocysteine in venous thrombosis. Haemostasis 21:51, 1991[Medline] [Order article via Infotrieve] 35. Amundsen T, Ueland PM, Waage A: Plasma homocysteine levels in patients with deep venous thrombosis. Arterioscler Thromb Vasc Biol 15:1321, 1995[Abstract/Free Full Text] 36. Bienvenu T, Ankri A, Chadefaux B, Montalescot G, Kamoun P: Elevated total plasma homocysteine, a risk factor for thrombosis. Relation to coagulation and fibrinolytic parameters. Thromb Res 70:123, 1993[Medline] [Order article via Infotrieve] 37. (abstr) Trillot N, Preudhomme C, Alhenc-Gelas M, Gaveriaux V, Bauters A, Gandrille S, Aiach M, Jude B: Thermolabile methylenetetrahydrofolate reductase (MTHFR) does not modify the risk for thromboembolism in subjects with heterozygous factor V Leiden. Blood 88:284a, 1996 38. Finkelstein JD, Martin JJ: Methionine metabolism in mammals. Distribution of homocysteine between competing pathways. J Biol Chem 259:9508, 1984[Abstract/Free Full Text] 39. Selhub J, Miller JW: The pathogenesis of homocysteinemia: Interruption of the coordinate regulation by S-adenosylmethionine of the remethylation and transsulfuration of homocysteine. Am J Clin Nutr 55:131, 1992[Abstract/Free Full Text] 40. Applegarth DA, Hardwick DF, Ingram F, Auckland NL, Bozoian G: Excretion of S-adenosylmethionine and S-adenosylhomocysteine in homocystinuria. N Engl J Med 285:1265, 1971 © 1998 by The American Society of Hematology.   0006-4971/98/91-0028$3.00/0 CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: S. Kishi, J. Griener, C. Cheng, S. Das, E. H. Cook, D. Pei, M. Hudson, J. Rubnitz, J. T. Sandlund, C.-H. Pui, et al. Homocysteine, Pharmacogenetics, and Neurotoxicity in Children With Leukemia J. Clin. Oncol., August 15, 2003; 21(16): 3084 - 3091. [Abstract] [Full Text] [PDF] M. A. Crowther and J. G. Kelton Congenital Thrombophilic States Associated with Venous Thrombosis: A Qualitative Overview and Proposed Classification System Ann Intern Med, January 21, 2003; 138(2): 128 - 134. [Abstract] [Full Text] [PDF] K. G. Mann and M. Kalafatis Factor V: a combination of Dr Jekyll and Mr Hyde Blood, January 1, 2003; 101(1): 20 - 30. [Full Text] [PDF] P. M Ueland, H. Refsum, S. A. Beresford, and S. E. Vollset The controversy over homocysteine and cardiovascular risk Am. J. Clinical Nutrition, August 1, 2000; 72(2): 324 - 332. [Abstract] [Full Text] [PDF] M. Gaustadnes, N. Rudiger, K. Rasmussen, and J. Ingerslev Familial Thrombophilia Associated With Homozygosity for the Cystathionine {beta}-Synthase 833T->C Mutation Arterioscler. Thromb. Vasc. Biol., May 1, 2000; 20(5): 1392 - 1395. [Abstract] [Full Text] [PDF] B. A Cooper Review: high levels of homocysteine are associated with an increased risk for cardiovascular disease Evid. Based Med., March 1, 2000; 5(2): 63 - 63. [Full Text] This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Kluijtmans, L. A.J. Articles by Blom, H. J. Search for Related Content PubMed PubMed Citation Articles by Kluijtmans, L. A.J. Articles by Blom, H. J. Related Collections Hemostasis, Thrombosis, and Vascular Biology Social Bookmarking                   What's this?

	Copyright © 1998 by American Society of Hematology         Online ISSN: 1528-0020